Licensing and collaboration agreements enable development of enzyme replacement therapy for Homocystinuria, a rare metabolic disorder The University of Colorado (CU) has signed exclusive, worldwide licensing and collaboration agreements with rare-disease research-and-development firm Orphan Technologies Ltd to develop an enzyme replacement therapy for Cystathionine Beta-Synthase (CBS) -deficient homocystinuria, a rare, inherited metabolic disease that is often fatal at a young age...
via Health News from Medical News Today Read More Here..
No comments:
Post a Comment